Bellerophon Therapeutics Inc (BLPH) Quote

BLPH: effective Dec. 19,2024: Company Dissolved. Transfer Books Close

FINRA will delete the symbol:

https://otce.finra.org/otce/dailyList?viewType=Deletions

Will this company ever start again...did the study find anything positive out of all their data?

Did they go as far as bankruptcy?

BLPH delisted from the Nasdaq to the OTC. ***PPS dropped 68% from .39 to .1235 on ~14 million volume.

https://otce.finra.org/otce/dailyList?viewType=Additions

ten cents

RIP…

We all knew 33 cents was capitulation here! Congrats on those that waited and loaded with the maestro posse! Easy 10 banger here from those levels over next 36 months! Enjoy the ride, it will be bumpy but very profitable as always! 💪🏿😈

Yikes

This one is gonna run hard BB bands are pinched very tight.

failed trial

What happened?

NEWS

Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results
May 15, 2023 16:50 ET | Source: Bellerophon Therapeutics, Inc.


Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse®; Pivotal Top-line Data Expected in Mid-2023
WARREN, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2023.

“We are pleased with the progress we have made to date in 2023, highlighted by the completion of the blinded treatment phase of our ongoing pivotal Phase 3 REBUILD trial,” said Peter Fernandes, Bellerophon’s Chief Executive Officer. “We expect to report top-line results from the study in the middle of this year, a critical milestone for the Company. Importantly, following the recent license agreement with Baylor Bioscience and having successfully completed a $5 million equity financing, we are well-capitalized through this critical milestone.”

Clinical Program Highlights:

Fibrotic Interstitial Lung Disease (fILD)

REBUILD Phase 3 Study: The Company completed the blinded treatment phase of their pivotal Phase 3 REBUILD trial evaluating the safety and efficacy of INOpulse® for the treatment of patients with fILD and anticipates the availability of top-line results in mid-2023. A total of 145 fILD patients were enrolled and treated with either INOpulse at a dose of iNO45 or placebo. The Phase 3 program builds on positive top-line results from the Company’s previously reported Phase 2 studies for INOpulse® for the treatment of fILD which showed benefits in multiple cardiopulmonary parameters, including pulmonary vascular resistance and improvement in Moderate to Vigorous Physical Activity (MVPA) as measured by actigraphy after 16 weeks of chronic treatment. With a total of 145 patients enrolled, the study is powered >90%, (p-value of 0.01) for the primary endpoint of a change in MVPA measured by actigraphy. If approved, INOpulse would become the first therapy to treat a broad fILD population, including patients at low-, intermediate- and high-risk pulmonary hypertension.
Pulmonary Hypertension-Sarcoidosis (PH-Sarc)

Phase 2 Clinical Study: In December 2021, Bellerophon reported positive top-line data from the completed Phase 2 dose escalation study of INOpulse® evaluating the acute hemodynamic benefit of INOpulse® via right heart catheterization for the treatment of pulmonary hypertension associated with sarcoidosis (PH-Sarc). Based on the benefits demonstrated in hemodynamic parameters and favorable safety profile, Bellerophon designed and submitted to the FDA a proposed exploratory Phase 2 double-blinded placebo-controlled study to investigate the safety and efficacy of iNO45 dosed chronically for six months in patients with PH-Sarc. Subsequently, the Company received FDA clearance to conduct the study and Bellerophon is currently assessing the next steps for the study.

First Quarter Ended March 31, 2023, Financial Results:

Total licensing revenue for the three months ended March 31, 2023, was $5.6 million, which is related to the licensing agreement with Baylor BioSciences, Inc.

For the first quarter ended March 31, 2023, the Company reported net income of $2.8 million, or $0.27 per basic and diluted share, compared to a net loss of $5.6 million, or $(0.59) per basic and diluted share, in the first quarter ended March 31, 2022.

Research and development expenses for the first quarter ended March 31, 2023, were $2.6 million, compared to $4.4 million in the first quarter of 2022. The decrease was due to the completion of enrollment in the ongoing Phase 3 REBUILD trial in January 2023.

General and administrative expenses for the first quarter ended March 31, 2023, were $1.6 million, compared to $1.2 million in the first quarter of 2022. The increase was primarily due to an increase in general consulting costs and an increase in stock-based compensation.

Balance Sheet:

As of March 31, 2023, the Company had unrestricted cash and cash equivalents of $15.2 million, compared to unrestricted cash and cash equivalents of $6.9 million as of December 31, 2022. Bellerophon’s capital position as of March 31, 2023, is reflective of the transactions which closed in the first quarter of 2023. These transactions included $1.7 million net proceeds from the sale of the Company’s net operating losses and research and development credits under the State of New Jersey’s Technology Business Tax Certificate Transfer Program in January 2023, net proceeds of approximately $5 million related to the licensing agreement with Baylor BioSciences, and net proceeds of approximately $5 million from the registered direct offering, which closed in March 2023.

About Bellerophon

Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.

Its got to be relatively low with those kind of spreads at times.

Lol …one needs a flashlight to find the float .
BLPH

Cricket and frog.. lol

It does jump like a cricket…lol
BLPH

This is must own ticker, a must. It has 5 times potential from here.

That would be fantastic!
Thank you Dino.
BLPH

identical setup as what NVA*X did. I believe when the data comes out this will trade easily over 30 dollars.

Great!
BLPH

Still here, with all my shares, going no where until the data is released, I decide from there.

It’s happening!!!
BLPH

Thank you Dino great to know all this!
BLPH

It's positive, yes Tang Capital took a passive position. This is all where it started with NVAX, with direct offering at $2.00 and they walked it up and did more again and again and finally hit 300 dollars, grant it covid era and totally different market, but this is cancer, I think this will do really well with positive data coming out by end of 2nd quarter.

Positive or negative? Tia
I did some research found some passive stake by Tang Capital Partners 9.99% which is positive but not short term also they just had an offering dunno anymore, last thing chart seems ready for take off….but that is relative imo.
BLPH

Negative? I don’t know about it then.
BLPH

Euro, I believe something is happening with BLPH.

Thank you I didn't know going to add some.
BLPH

No, I mean data.

Lol... you're likely correct and below 7 is a great opportunity to enter/add with such a tiny float... Btw do you mean earnings?
BLPH

Every time it wants to run, people sell. They are due for news between now and end of June. So people buy in the hopes of news after hours and when there is no news, they sell only to buy back the next day. That has been the pattern so far.

About to do it !!!
BLPH

Cmon!!! pop!!

BLPH getting ready to pop. 9.40 blue skies above.

Futures are ripping hard, only a matter of time before BLPH does a double from there.

Watch this between Monday-Tuesday, something tells me, it is about to move fast into the teens.

BLPH will do what NVA*X did couple of years back.

BLPH is next weeks runner, runner.

What a impressive run

BLPH: And THIS time around, EASY money all day long!!

Wild

News leak?

8k out

Nice to see this one green again...MBGA

BLPH: E-Turd will NOT accept orders on this right now! (What's happening here?? And it ain't no SKULL-&-CROSSBONES routine.)

BLPH: HUUUUUGE morn. gapper!!! (Be careful.)

RIP 3.40 chasers.

$BLPH: WOW..... now 2.50


Whatta runnerrrrrrrrrrrrrrrrrrrrr


Excellent call


GO $BLPH

Pre mkt 1.69 was a nice entry.

Where is everyone? This is getting shirts wrecked.

Thursday King stock of the day 2.16

Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
09/27/2022 12:30 PM
New study size of 140 patients for the REBUILD Study, without modifying trial objective or endpoints and maintaining power of >90% for the primary endpoint Independent Data Monitoring Committee agreed that the new targeted study size is appropriate Enrollment now expected to conclude in Q1 2023,